Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43810 | 0.98 | AKR1C1 (0.68) | AKR1C1HDAC4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2184245 | 0.96 | AKR1C1 (0.64) | AKR1C1HDAC4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2722547 | 0.91 | AKR1C1 (0.57) | AKR1C1HDAC4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL501923 | 0.91 | AKR1C1 (0.57) | AKR1C1HDAC4MEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1804765 | 0.89 | AKR1C1 (0.55) | AKR1C1HDAC4MEN1KMT2AHSD11B1 | |
| SCHEMBL4558509 | 0.83 | HDAC4 (0.51) | AKR1C1HDAC4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL65167 | 0.83 | AKR1C1 (1.00) | AKR1C1HDAC4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3107522 | 0.83 | AKR1C1 (0.76) | AKR1C1HDAC4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL476403 | 0.82 | OPRM1 (0.58) | AKR1C1HDAC4HSD11B1OPRL1 | |
| SCHEMBL2703559 | 0.82 | ALDH1A1 (0.58) | AKR1C1SMN1; SMN2LMNANPSR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375549-A | Method and system for synthesizing amide compound from nitrile compound | 深圳湾实验室 | 2023-07-04 | — | — | CN | claimed |
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| EP-2007380-B1 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2011-09-14 | — | — | EP | claimed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | claimed |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | VM THERAPEUTICS LLC | 2011-03-17 | — | — | US | claimed |
| WO-2007044729-A2 | N- (3-AMINO-QUINOXALIN-2-YL) -SULFONAMIDE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| CN-1946395-A | 1H-thieno [2, 3-c ] pyrazole derivatives useful as kinase inhibitors | PHARMACIA ITALIA SPA (IT) | 2007-04-11 | — | — | CN | claimed |
| EP-1711177-A1 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS | Pfizer Italia S.r.l. (IT) | 2006-10-18 | — | — | EP | claimed |
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-25 | — | — | US | claimed |
| WO-2005074922-A1 | 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | PFIZER ITALIA S.R.L. (IT) | 2005-08-18 | — | — | WO | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | claimed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | claimed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | claimed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | AKR1C1 490/4885HDAC4 2927/4885MEN1 2931/4885 |
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | MAP3K19, MAP3K1, MAP3K3 | AKR1C1 1337/4885HDAC4 1756/4885MEN1 2954/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | AKR1C1 3032/4885HDAC4 271/4885MEN1 2324/4885 |
| US-20110065703-A1 | NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS | CACNA1G, CACNA1C, CACNA1B | AKR1C1 3659/4885HDAC4 1042/4885MEN1 3058/4885 |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | AKR1C1 186/4885HDAC4 1492/4885MEN1 4040/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | AKR1C1 342/4885HDAC4 3184/4885MEN1 2107/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | AKR1C1 3032/4885HDAC4 271/4885MEN1 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.